Biomarker Test Developed for Chronic Fatigue Syndrome
By LabMedica International staff writers Posted on 16 May 2019 |

Image: A nanoelectronics assay: stressed blood cells could be a biomarker for chronic fatigue (Photo courtesy of The Scientist).
Myalgic encephalomyelitis, or chronic fatigue syndrome (ME/CFS), is a serious condition that may affect up to 2.5 million people in the USA. Symptoms include extreme tiredness, difficulty sleeping, trouble with thinking and remembering things, muscle pain and aches, a recurring sore throat, and tender lymph nodes.
Currently, physicians can only diagnose ME/CFS by examining a person's symptoms and medical history, and by excluding other possible illnesses. This can make the diagnosis process difficult, lengthy, and inaccurate. A new diagnostic test looks at how a person's immune cells react to stress.
Scientists at the Stanford University School of Medicine (Stanford, CA, USA) have developed a nanoelectronics assay designed as an ultrasensitive assay capable of directly measuring biomolecular interactions in real time, at low cost, and in a multiplex format. The team applied the test to the blood samples of 40 people, 20 of who had ME/CFS and 20 whom did not.
The scientists used a nanoelectronic assay, which measures small changes in energy to assess the health of immune cells and blood plasma, to see how the immune cells and blood plasma process stress. To develop the test, the team took advantage of "advancements in micro/nanofabrication, direct electrical detection of cellular and molecular properties, microfluidics, and artificial intelligence techniques."
The test detects "biomolecular interactions in real time" by using thousands of electrodes to create an electrical current, and by using small chambers that contain blood samples with only immune cells and blood plasma. Inside the small chambers, the immune cells and plasma interact with the electrical current, altering its flow. The scientists used salt to stress the blood samples of some people with ME/CFS and some people without the condition. They then assessed the changes in electrical current. Their test accurately identified all of the people with ME/CFS without misidentifying any of the people who did not have the condition.
The team concluded that they had observed robust impedance modulation difference of the samples in response to hyperosmotic stress can potentially provide a unique indicator of ME/CFS. Moreover, using supervised machine learning algorithms, they developed a classifier for ME/CFS patients capable of identifying new patients, required for a robust diagnostic tool.
Rahim Esfandyarpour, PhD, a Bioengineer and first author of the study, said, “Using the nanoelectronics assay, we can add controlled doses of many different potentially therapeutic drugs to the patient's blood samples and run the diagnostic test again.” The study was published on April 29, 2019, in the journal Proceedings of the National Academy of Sciences.
Related Links:
Stanford University School of Medicine
Currently, physicians can only diagnose ME/CFS by examining a person's symptoms and medical history, and by excluding other possible illnesses. This can make the diagnosis process difficult, lengthy, and inaccurate. A new diagnostic test looks at how a person's immune cells react to stress.
Scientists at the Stanford University School of Medicine (Stanford, CA, USA) have developed a nanoelectronics assay designed as an ultrasensitive assay capable of directly measuring biomolecular interactions in real time, at low cost, and in a multiplex format. The team applied the test to the blood samples of 40 people, 20 of who had ME/CFS and 20 whom did not.
The scientists used a nanoelectronic assay, which measures small changes in energy to assess the health of immune cells and blood plasma, to see how the immune cells and blood plasma process stress. To develop the test, the team took advantage of "advancements in micro/nanofabrication, direct electrical detection of cellular and molecular properties, microfluidics, and artificial intelligence techniques."
The test detects "biomolecular interactions in real time" by using thousands of electrodes to create an electrical current, and by using small chambers that contain blood samples with only immune cells and blood plasma. Inside the small chambers, the immune cells and plasma interact with the electrical current, altering its flow. The scientists used salt to stress the blood samples of some people with ME/CFS and some people without the condition. They then assessed the changes in electrical current. Their test accurately identified all of the people with ME/CFS without misidentifying any of the people who did not have the condition.
The team concluded that they had observed robust impedance modulation difference of the samples in response to hyperosmotic stress can potentially provide a unique indicator of ME/CFS. Moreover, using supervised machine learning algorithms, they developed a classifier for ME/CFS patients capable of identifying new patients, required for a robust diagnostic tool.
Rahim Esfandyarpour, PhD, a Bioengineer and first author of the study, said, “Using the nanoelectronics assay, we can add controlled doses of many different potentially therapeutic drugs to the patient's blood samples and run the diagnostic test again.” The study was published on April 29, 2019, in the journal Proceedings of the National Academy of Sciences.
Related Links:
Stanford University School of Medicine
Latest Technology News
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
- First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer
- Optical Biosensor Rapidly Detects Monkeypox Virus at Point of Care
- Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients
- New Noninvasive Methods Detect Lead Exposure Faster, Easier and More Accurately at POC
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
Approximately one in three women aged 14-49 in the United States will experience bacterial vaginosis (BV), a vaginal bacterial imbalance, at some point in their lives. Around 50% of BV cases do not present... Read more
Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
Hepatitis B, an inflammation of the liver caused by the hepatitis B virus (HBV), is the second-leading infectious cause of death globally, following tuberculosis. This viral infection can result in serious... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreIndustry
view channel
Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows
Royal Philips (Amsterdam, The Netherlands) has expanded its partnership with Ibex Medical Analytics (Tel Aviv, Israel) and released the new Philips IntelliSite Pathology Solution (PIPS) to further accelerate... Read more
Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’
Grifols (Barcelona, Spain), a manufacturer of plasma-derived medicines and innovative diagnostic solutions, has entered into a strategic agreement with Inpeco (Novazzano, Switzerland), a global leader... Read more